FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999263142> ?p ?o ?g. }

• W2999263142 endingPage "805" @default.
• W2999263142 startingPage "801" @default.
• W2999263142 abstract "Abstract Bilastine, a second-generation antihistamine, is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children aged ≥ 6 years. Pharmacokinetic data for children aged 6–11 years were extracted post hoc from a study in which children (2–11 years) with allergic rhinoconjunctivitis or urticaria received oral bilastine (10 mg/day). Maximum plasma concentration ( C max ) and area under the plasma concentration curve (AUC) data were compared with adult pharmacokinetic data from seven clinical studies (bilastine 20 mg/day). Safety data for children aged 6–11 years were extracted post hoc from a phase III randomized controlled trial of children (2–11 years) with allergic rhinoconjunctivitis or chronic urticaria receiving once-daily bilastine 10 mg or placebo for 12 weeks. Exposure and C max values were similar for children (6–11 years) and adults: median pediatric/adult ratios for AUC 0–24 and C max were 0.93 and 0.91, respectively. There was no significant difference in the incidence of treatment-emergent adverse in children (6–11 years) receiving bilastine 10 mg or placebo. Conclusion : Pharmacokinetic and safety analyses in children aged 6–11 years support the suitability of the pediatric dose of bilastine 10 mg and confirm that the safety profiles of bilastine and placebo are similar. What is Known: • Bilastine, a second-generation antihistamine, is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in adults (20 mg/day) and children aged ≥ 6 years (10 mg/day). • An ontogenic model based on adult data and pharmacokinetic/pharmacodynamic simulations supported the selection of a bilastine dose of 10 mg/day in children aged 2–11 years. Bilastine 10 mg/day was shown to have a safety profile similar to that of placebo in a large phase III randomized clinical trial in children aged 2–11 years. What is New: • As bilastine is approved in Europe for children aged ≥6 years, the current study reports the results of two post hoc analyses of pharmacokinetic and safety data in children aged 6–11 years. • Analysis of pharmacokinetic and safety data in children aged 6–11 years supports the suitability of the pediatric dose of bilastine 10 mg and confirms that its safety profile is similar to that of placebo." @default.
• W2999263142 created "2020-01-23" @default.
• W2999263142 creator A5000391786 @default.
• W2999263142 creator A5017373251 @default.
• W2999263142 creator A5021536267 @default.
• W2999263142 creator A5026061400 @default.
• W2999263142 creator A5044977738 @default.
• W2999263142 creator A5047390918 @default.
• W2999263142 creator A5078734965 @default.
• W2999263142 date "2020-01-09" @default.
• W2999263142 modified "2023-09-24" @default.
• W2999263142 title "Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria" @default.
• W2999263142 cites W1596034103 @default.
• W2999263142 cites W2000455036 @default.
• W2999263142 cites W2040761998 @default.
• W2999263142 cites W2113512009 @default.
• W2999263142 cites W2160918196 @default.
• W2999263142 cites W2274239973 @default.
• W2999263142 cites W2336895030 @default.
• W2999263142 cites W2610295748 @default.
• W2999263142 cites W2764189638 @default.
• W2999263142 cites W2910270552 @default.
• W2999263142 cites W2901631443 @default.
• W2999263142 doi "https://doi.org/10.1007/s00431-019-03559-6" @default.
• W2999263142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7160087" @default.
• W2999263142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31919579" @default.
• W2999263142 hasPublicationYear "2020" @default.
• W2999263142 type Work @default.
• W2999263142 sameAs 2999263142 @default.
• W2999263142 citedByCount "8" @default.
• W2999263142 countsByYear W29992631422021 @default.
• W2999263142 countsByYear W29992631422022 @default.
• W2999263142 countsByYear W29992631422023 @default.
• W2999263142 crossrefType "journal-article" @default.
• W2999263142 hasAuthorship W2999263142A5000391786 @default.
• W2999263142 hasAuthorship W2999263142A5017373251 @default.
• W2999263142 hasAuthorship W2999263142A5021536267 @default.
• W2999263142 hasAuthorship W2999263142A5026061400 @default.
• W2999263142 hasAuthorship W2999263142A5044977738 @default.
• W2999263142 hasAuthorship W2999263142A5047390918 @default.
• W2999263142 hasAuthorship W2999263142A5078734965 @default.
• W2999263142 hasBestOaLocation W29992631421 @default.
• W2999263142 hasConcept C112705442 @default.
• W2999263142 hasConcept C120665830 @default.
• W2999263142 hasConcept C121332964 @default.
• W2999263142 hasConcept C126322002 @default.
• W2999263142 hasConcept C142724271 @default.
• W2999263142 hasConcept C197934379 @default.
• W2999263142 hasConcept C204787440 @default.
• W2999263142 hasConcept C27081682 @default.
• W2999263142 hasConcept C2776880894 @default.
• W2999263142 hasConcept C42219234 @default.
• W2999263142 hasConcept C61511704 @default.
• W2999263142 hasConcept C67761136 @default.
• W2999263142 hasConcept C71924100 @default.
• W2999263142 hasConceptScore W2999263142C112705442 @default.
• W2999263142 hasConceptScore W2999263142C120665830 @default.
• W2999263142 hasConceptScore W2999263142C121332964 @default.
• W2999263142 hasConceptScore W2999263142C126322002 @default.
• W2999263142 hasConceptScore W2999263142C142724271 @default.
• W2999263142 hasConceptScore W2999263142C197934379 @default.
• W2999263142 hasConceptScore W2999263142C204787440 @default.
• W2999263142 hasConceptScore W2999263142C27081682 @default.
• W2999263142 hasConceptScore W2999263142C2776880894 @default.
• W2999263142 hasConceptScore W2999263142C42219234 @default.
• W2999263142 hasConceptScore W2999263142C61511704 @default.
• W2999263142 hasConceptScore W2999263142C67761136 @default.
• W2999263142 hasConceptScore W2999263142C71924100 @default.
• W2999263142 hasIssue "5" @default.
• W2999263142 hasLocation W29992631421 @default.
• W2999263142 hasLocation W29992631422 @default.
• W2999263142 hasLocation W29992631423 @default.
• W2999263142 hasOpenAccess W2999263142 @default.
• W2999263142 hasPrimaryLocation W29992631421 @default.
• W2999263142 hasRelatedWork W1580426574 @default.
• W2999263142 hasRelatedWork W2089620537 @default.
• W2999263142 hasRelatedWork W2275480158 @default.
• W2999263142 hasRelatedWork W2331056681 @default.
• W2999263142 hasRelatedWork W2371214482 @default.
• W2999263142 hasRelatedWork W2751938426 @default.
• W2999263142 hasRelatedWork W2929987155 @default.
• W2999263142 hasRelatedWork W3095306390 @default.
• W2999263142 hasRelatedWork W4233016836 @default.
• W2999263142 hasRelatedWork W4238089809 @default.
• W2999263142 hasVolume "179" @default.
• W2999263142 isParatext "false" @default.
• W2999263142 isRetracted "false" @default.
• W2999263142 magId "2999263142" @default.
• W2999263142 workType "article" @default.